Appointment | December 01, 2021
Sygnature Discovery appoints Louisa Jordison as Chief Financial Officer
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The new manufacturing facility will be built at a subsidiary of Adcock Ingram and will commence operation in March 23
Subscribe To Our Newsletter & Stay Updated
